Aastrom Treats Patients in Adult Stem Cell Clinical Trial for Osteonecrosis

ANN ARBOR, Mich., Jan 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced that the first two patients have been treated in a pivotal clinical trial utilizing the Company’s Tissue Repair Cells (TRCs) for the treatment of osteonecrosis (also known as avascular necrosis) of the femoral head. The pivotal trial sponsored by Aastrom is being conducted at Centro Medico Teknon (Teknon) located in Barcelona, Spain.

Source: Aastrom Biosciences, Inc.